The EAU acknowledges the pivotal role that European Union regulation plays in the medical practice of its members.
As the European Commission embarks on an ambitious cancer plan, the EAU is engaging to ensure that prostate cancer is tackled at European level, and that our scientific expertise can bring value to the plans.
Please click here for more information.
The EAU is engaging on the policy direction taken by the EU in terms of funding for medical research and innovation. Horizon Europe will be the new framework programme from 2021-2027, which will be of relevance to many EAU members.
Read more about Horizon Europe here
ERNs are an exciting new form of cooperation at European level between healthcare providers with specialised expertise with the aim of improving care for patients with rare diseases or complex conditions. eUROGEN aims to improve diagnosis, create more equitable access to high-quality treatment and care for patients with rare urogenital diseases and complex conditions needing highly specialised surgery. eUROGEN has worked with the EAU in close partnership with all national European urological societies.
Read more on the eUROGEN website
Medical devices, from gauze to implants, are an integral part of urological practice and the quality and efficacy of urological care are enhanced by innovations in the sector.
The European Union seeks to ensure the highest level of patient safety, whilst maintaining competitiveness in the sector through regulation on market access, international trade and regulatory convergence.
Clinical trials are vital to the improvement of urological care. The new EU Clinical Trials regulation, applicable as of May 2016, stimulates clinical trials and seeks the highest standard for patient safety.
The mobility of European medical practitioners within the continent has increased rapidly in the last decade. The EAU supports this by strengthening the network of European urologists and exchanging information and best practices.
The European Commission is revising the existing EU Data Protection Directive to ensure a more harmonized approach to data protection and privacy across the European Union. However, this could hinder research involving personal data, such as genetic research.
Advanced therapies, whether genetic, cell therapy or tissue engineering, have huge potential for urological patients. The EAU supports EU regulation designed to improve market access and foster competitiveness in the area of advanced therapy medicinal products that guarantee patient safety.
Continuing Medical Education (CME) programmes are not implemented fully in many Member States. Adoption of urological guidelines and CME validation are key topics in which the EAU can contribute to policy improvements in this area.